2-((1S,3R)-3-(3-aminopyridin-4-yl)cyclohexyl)isoindoline-1,3-dione | 1405127-95-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-((1S,3R)-3-(3-aminopyridin-4-yl)cyclohexyl)isoindoline-1,3-dione
• 英文别名: 2-[(1S,3R)-3-(3-aminopyridin-4-yl)cyclohexyl]isoindole-1,3-dione
• CAS: 1405127-95-8
• 化学式: C₁₉H₁₉N₃O₂
• 分子量: 321.379
• InChiKey: JHDJVLQRIAPHBQ-OLZOCXBDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  76.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-((1S,3R)-3-(3-aminopyridin-4-yl)cyclohexyl)isoindoline-1,3-dione 在 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 肼 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 14.0h， 生成 N-(4-((1R,3S)-3-aminocyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide
  参考文献：
  名称：

  Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies

  摘要：

  Pan proviral insertion site of Moloney murine leukemia (PIM) 1, 2, and 3 kinase inhibitors have recently begun to be tested in humans to assess whether pan PIM kinase inhibition may provide benefit to cancer patients. Herein, the synthesis, in vitro activity, in vivo activity in an acute myeloid leukemia xenograft model, and preclinical profile of the potent and selective pan PIM kinase inhibitor compound 8 (PIM447) are described. Starting from the reported aminopiperidyl pan PIM kinase inhibitor compound 3, a strategy to improve the microsomal stability was pursued resulting in the identification of potent aminocyclohexyl pan PIM inhibitors with high metabolic stability. From this aminocyclohexyl series, compound 8 entered the clinic in 2012 in multiple myeloma patients and is currently in several phase 1 trials of cancer patients with hematological malignancies.

  DOI：

  10.1021/acs.jmedchem.5b01275
• 作为产物：
  描述：

  3-(trifluoromethanesulfonyloxy)-2-cyclohexen-1-one 在 sodium tetrahydroborate 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 cerium(III) chloride heptahydrate 、 偶氮二甲酸二叔丁酯 、 palladium 10% on activated carbon 、 氢气 、 potassium acetate 、 sodium carbonate 、 三苯基膦 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 正己烷 为溶剂， 110.0 ℃ 、2.76 MPa 条件下， 反应 56.0h， 生成 2-((1S,3R)-3-(3-aminopyridin-4-yl)cyclohexyl)isoindoline-1,3-dione 、 2-(3-(3-aminopyridin-4-yl)cyclohexyl)isoindoline-1,3-dione
  参考文献：
  名称：

  Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies

  摘要：

  Pan proviral insertion site of Moloney murine leukemia (PIM) 1, 2, and 3 kinase inhibitors have recently begun to be tested in humans to assess whether pan PIM kinase inhibition may provide benefit to cancer patients. Herein, the synthesis, in vitro activity, in vivo activity in an acute myeloid leukemia xenograft model, and preclinical profile of the potent and selective pan PIM kinase inhibitor compound 8 (PIM447) are described. Starting from the reported aminopiperidyl pan PIM kinase inhibitor compound 3, a strategy to improve the microsomal stability was pursued resulting in the identification of potent aminocyclohexyl pan PIM inhibitors with high metabolic stability. From this aminocyclohexyl series, compound 8 entered the clinic in 2012 in multiple myeloma patients and is currently in several phase 1 trials of cancer patients with hematological malignancies.

  DOI：

  10.1021/acs.jmedchem.5b01275

文献信息

• [EN] ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS<br/>[FR] COMPOSÉS DE PYRIDAZINE BICYCLIQUES CONDENSÉS SUBSTITUÉS PAR UN GROUPE ARYLE
  申请人：NOVARTIS AG

  公开号：WO2014099880A1

  公开（公告）日：2014-06-26

  The present invention provides a compound of formula (I) as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.

  本发明提供了一种如下所述的化合物(I)，以及其药用可接受的盐、对映体、旋转异构体、互变异构体或消旋体。还提供了使用化合物(I)治疗由PIM激酶介导的疾病或病况的方法，以及包含这些化合物的药物组合物。
• [EN] BICYCLIC PYRIDAZINE COMPOUNDS AS PIM INHIBITORS<br/>[FR] COMPOSÉS PYRIDAZINES BICYCLIQUES EN TANT QU'INHIBITEURS DE PIM
  申请人：AMGEN INC

  公开号：WO2012148775A1

  公开（公告）日：2012-11-01

  The invention relates to bicyclic compounds of formulas I and I', and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  该发明涉及公式I和I'的双环化合物及其盐。在某些实施例中，该发明涉及Pim-1和/或Pim-2以及/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，该发明涉及包含本文披露的化合物的药物组合物，以及它们在预防和治疗Pim激酶相关疾病和病症，尤其是癌症中的应用。
• Bicyclic Pyridazine Compounds as PIM Inhibitors
  申请人：D'amico Derin C.

  公开号：US20140221344A1

  公开（公告）日：2014-08-07

  The invention relates to bicyclic compounds of formulas I and I′, and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

  本发明涉及式I和I'的双环化合物及其盐。在某些实施例中，本发明涉及Pim-1和/或Pim-2和/或Pim-3蛋白激酶活性或酶功能的抑制剂或调节剂。在更进一步的实施例中，本发明涉及包含所述化合物的制药组合物，以及它们在预防和治疗Pim激酶相关疾病和病症，尤其是癌症方面的应用。
• ARYL-SUBSTITUTED FUSED BICYCLIC PYRIDAZINE COMPOUNDS
  申请人：BURGER Matthew

  公开号：US20150336960A1

  公开（公告）日：2015-11-26

  The present invention provides a compound of formula (I) as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula (I), and pharmaceutical compositions comprising such compounds.

  本发明提供了式（I）的化合物，以及其药学上可接受的盐、对映体、旋转异构体、互变异构体或外消旋体。还提供了使用式（I）化合物治疗由PIM激酶介导的疾病或病况的方法，以及包含这些化合物的制药组合物。
• US9187486B2
  申请人：——

  公开号：US9187486B2

  公开（公告）日：2015-11-17